Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK/PD of REGN7544 in Healthy Adults
NCT05970718Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2023
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of baloncibart in sepsis and postural orthostatic tachycardia syndrome (POTS) (11 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of Treatment Emergent Adverse Events and Severity of Treatment Emergent Adverse Events. Started Aug 2023; status: completed.
02
Drugs
baloncibart
03
Conditions
sepsispostural orthostatic tachycardia syndrome (POTS)
Beyond the preview
Go deeper on NCT05970718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05970718.